Skip to Content
Merck
CN

V900439

Uracil

Vetec, reagent grade, 98%

Synonym(s):

2,4(1H,3H)-Pyrimidinedione, 2,4-Dihydroxypyrimidine, 2,4-Pyrimidinediol

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C4H4N2O2
CAS Number:
Molecular Weight:
112.09
EC Number:
200-621-9
UNSPSC Code:
41106305
PubChem Substance ID:
Beilstein/REAXYS Number:
507828
MDL number:
Assay:
98%
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

reagent grade

product line

Vetec

assay

98%

mp

>300 °C (lit.)

SMILES string

O=C1NC=CC(=O)N1

InChI

1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)

InChI key

ISAKRJDGNUQOIC-UHFFFAOYSA-N

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Explore all of our products under Uracil


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Sandra M Carvalho et al.
PloS one, 8(3), e58492-e58492 (2013-03-19)
Links between carbohydrate metabolism and virulence in Streptococcus pneumoniae have been recurrently established. To investigate these links further we developed a chemically defined medium (CDM) and standardized growth conditions that allowed for high growth yields of the related pneumococcal strains
William B White et al.
The New England journal of medicine, 369(14), 1327-1335 (2013-09-03)
To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new
Jordan J Feld et al.
The New England journal of medicine, 370(17), 1594-1603 (2014-04-12)
The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus



Global Trade Item Number

SKUGTIN
V900439-100G04061833468395
V900439-500G04061833493540